Teva: Payers Hold The Cards On Material 2023 Adalimumab Opportunity
Company ‘Would Be Disappointed If It’s Not A Material Event In 2023’
Fresh from partner Alvotech resolving patent litigation in the US for its proposed Humira biosimilar, Teva management has detailed the firm’s expectations around the product and the crucial issue of supply.
